Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) Equity Average (2019 - 2025)

Silo Pharma's Equity Average history spans 7 years, with the latest figure at $5.0 million for Q3 2025.

  • For Q3 2025, Equity Average fell 22.09% year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, down 22.09%, while the annual FY2024 figure was $5.6 million, 32.13% down from the prior year.
  • Equity Average for Q3 2025 was $5.0 million at Silo Pharma, up from $4.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $11.1 million in Q4 2022 and bottomed at $2.8 million in Q1 2021.
  • The 5-year median for Equity Average is $6.8 million (2023), against an average of $7.0 million.
  • The largest annual shift saw Equity Average skyrocketed 2035.12% in 2021 before it plummeted 42.03% in 2024.
  • A 5-year view of Equity Average shows it stood at $9.6 million in 2021, then grew by 15.52% to $11.1 million in 2022, then crashed by 38.39% to $6.8 million in 2023, then dropped by 13.58% to $5.9 million in 2024, then fell by 16.0% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for SILO's Equity Average are $5.0 million (Q3 2025), $4.5 million (Q2 2025), and $4.5 million (Q1 2025).